← Guides

GLP-1: semaglutide and tirzepatide explained

GLP-1 (glucagon-like peptide-1) is an incretin hormone the body releases naturally after eating. In recent years, molecules that mimic its action — semaglutide and tirzepatide — have become some of the most studied and talked-about metabolic drugs. This guide explains, at an educational level, what the GLP-1 system is and how these two molecules differ. The starting point and central caveat: they are approved medicines that require a prescription and medical supervision. This is not medical advice or a recommendation for use, and it contains no dosing instructions. Material sold without a prescription as 'research use only' is not approved for human use and carries additional risks.

What the GLP-1 system is (incretins)

Incretins are gut hormones released when we eat that help regulate glucose. GLP-1 is one of them: it stimulates insulin secretion in a glucose-dependent way (only when needed), suppresses glucagon, slows gastric emptying, and acts on brain centers that regulate appetite, increasing satiety. Native GLP-1 is broken down within minutes by the enzyme DPP-4, so its effect is fleeting. The other major incretin is GIP (glucose-dependent insulinotropic polypeptide), which matters for understanding tirzepatide. Grasping this system is the foundation for understanding why these drugs were designed.

Semaglutide: a GLP-1 receptor agonist

Semaglutide is a synthetic analog of human GLP-1 (about 94% homology with the native hormone) with modifications that make it resistant to DPP-4 degradation and extend its half-life to roughly one week. As a selective GLP-1 receptor agonist, it reproduces the natural hormone's actions but in a sustained way. It is approved by the FDA and EMA and marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management). It is a genuine prescription biologic, consistent with its hub profile. It requires a prescription and medical follow-up.

Tirzepatide: a dual GLP-1/GIP agonist

Tirzepatide is a synthetic 39-amino-acid peptide engineered as the first approved dual agonist: it activates both the GLP-1 receptor and the GIP receptor at once. Adding the GIP signal to the GLP-1 signal is the key conceptual difference from semaglutide. It is a larger, structurally more complex molecule, demanding very precise synthesis. It is approved by the FDA and EMA and marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). In short: semaglutide acts on one target (GLP-1); tirzepatide on two (GLP-1 and GIP). Both require a prescription and supervision.

Approved drug versus 'research' material

This is the single most important distinction in the guide. The approved drug is a pharmaceutical product with verified composition, purity and dose, studied in registered trials and used under prescription and medical supervision that manages adverse effects and contraindications. Gray-market material sold 'for research use only' or compounded is a different thing: it is not FDA/EMA-approved for human use, lacks quality assurance, and regulators have issued warnings about impurities, incorrect salt forms and mislabeled concentrations, with associated adverse events. Studying the pharmacology is not an endorsement of that material or of using it without a physician.

Frequently asked questions

What is GLP-1 and what is it for?

GLP-1 is an incretin hormone the gut releases when we eat. It regulates glucose by stimulating insulin when needed, suppressing glucagon, slowing gastric emptying and increasing satiety. Drugs that mimic this action, such as semaglutide, are approved by the FDA and EMA for glycemic control in type 2 diabetes and for chronic weight management, always by prescription and under medical supervision. This guide is educational and not medical advice.

How do semaglutide and tirzepatide differ?

Semaglutide is a selective GLP-1 receptor agonist: it acts on a single target. Tirzepatide is a dual agonist that activates both the GLP-1 and GIP receptors, adding a second incretin pathway. Tirzepatide is also a larger, more complex molecule. Both are FDA- and EMA-approved (Ozempic/Wegovy/Rybelsus and Mounjaro/Zepbound respectively) and both require a prescription. Consistent with their hub profiles; no dosing figures given.

Can they be used without a prescription if they are 'research grade'?

Not as a substitute for the approved drug. Semaglutide and tirzepatide are prescription medicines that require a prescription and medical supervision. Material sold without a prescription as 'research use only' or compounded is not FDA/EMA-approved for human use, offers no quality assurance, and has been the subject of regulatory warnings about impurities and dosing errors. This guide does not encourage the gray market or provide usage instructions.

✓ Last reviewed · 2026-07-22